Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT04834024

PHASE3

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Sponsor: Beijing Mabworks Biotech Co., Ltd.

View on ClinicalTrials.gov

Summary

This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.

Official title: A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

168

Start Date

2021-06-02

Completion Date

2025-03

Last Updated

2024-11-20

Healthy Volunteers

Conditions

Follicular Lymphoma and Marginal Zone Lymphoma

Interventions

DRUG

Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide

The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.

DRUG

lenalinomide

The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.

Inclusion Criteria: 1. Adult patients, \>=18 years of age; 2. Patients with either histologically documented CD20-positive FL, WHO grade 1, 2 or 3a 3. Evidence of refractory to rituximab 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 5. At least one bi-dimensionally measurable nodal or tumor lesion defined by CT scan as: greatest transverse diameter \> 1.5 cm and a short axis ≥ 10mm 6. Adequate hematologic function 7. Life expectancy \>5 years 8. Able and willing to provide written informed consent and to comply with the study protocol Exclusion Criteria: 1. Evidence of refractory to lenalinomide 2. Central nervous system lymphoma 3. Patients with progressive multifocalleukoencephalopathy (PML) 4. Prior use of any antibody therapy(except for Rituximab ) within 3 months of study start 5. Prior use of any anti-cancer vaccine 6. Prior administration of radiotherapy 42 days prior to study entry 7. Prior administration of chemotherapy 28 days prior to study entry 8. History of prior malignancy within the last 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma of the cervix 9. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy 10. Known hypersensitivity to thalidomide or lenalidomide 11. Regular treatment with corticosteroids prior to the start of cycle 1, unless administered for indications other than NHL at a dose equivalent to \< 20 mg/day prednisone 12. Any serious active disease or co-morbid medical condition (such as New York Heart Association Class II or IV cardiac disease, severe arrhythmia, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision) 13. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C(including HBsAg,HBcAb positive with abnormal HBV DAN or HCV RNA ) 14. Pregnant or lactating females

Locations (1)

Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, China